InMed Pharmaceuticals News | Press Releases

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Menu

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Press Releases

InMed Announces Changes to its Board of Directors

August 9, 2022

InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa

July 25, 2022

InMed Announces Appointment of Chief Operating Officer

July 18, 2022

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

July 12, 2022

InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

June 14, 2022

InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

June 9, 2022

InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

June 6, 2022

InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

June 2, 2022

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

May 13, 2022

InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV

May 2, 2022

InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert

April 28, 2022

InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert

April 28, 2022

InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

April 21, 2022

InMed Announces Management Changes

March 17, 2022

InMed to Present at the 34th Annual Roth Conference

March 8, 2022

InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica

February 15, 2022

InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update

February 14, 2022

InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022

February 10, 2022

InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

January 19, 2022

InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook

January 5, 2022

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Next »

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
Neurodegenerative Disease
Novel Cannabinoid Analogs

MANUFACTURING

Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing
BayMedica Cannabinoid Biosynthesis
Rare Cannabinoid Ingredients

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM
Filings
Presentations
Media

CORPORATE

Management
Board of Directors
Scientific Advisory Board
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.